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ABSTRACT   
Objective:  to assess advantages and drawbacks of  two recently proposed staging systems for Amyotrophic Lateral 
Sclerosis (ALS) - King’s College and MITOS staging system - in an incident, population-based cohort of ALS patients. 
Methods: Since 2009, a prospective registry records all incident cases of ALS in the Emilia Romagna region, Italy. For 
each patient, detailed clinical information, including the ALS functional rating scale (ALSFRS-R) score, is collected at 
each follow-up. 
Results: Our study on 545 incident cases confirmed that King’s College stages occur at predictable times throughout 
the disease course (at 40, 60 and 80% of the disease course) while MITOS stages are skewed towards later stages (35, 
67, 79, 100 and 104% of the disease course). In King’s College system there is a decrease in survival and an increase in 
deaths with escalating stages, while in the MITOS system survival curves pertaining to intermediate stages overlap and 
the number of deaths is fairly homogeneous throughout most stages.  
Conclusions: King’s College staging system has a higher homogeneity (i.e. smaller differences in survival among 
patients in the same stage),and a higher discriminatory ability (i.e. greater differences in survival among patients in 
different stages), being more suitable for individualized prognosis and for measuring efficacy of therapeutic 
interventions.   
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INTRODUCTION   
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive disability [1] and 
great inter-individual variability, making prognosis still a challenge. Although several prognostic models exist, based on 
clinical/demographic factors at diagnosis for prediction of survival, they do not include milestones, which are necessary 
for staging criteria [2]. A reliable staging system would be of great importance as it could help predicting prognosis, it 
would allow personalized counselling, and it would be useful for clinical trial conduction and resources allocation. 
The most widely used functional scale in ALS [the ALS Functional Rating Scale- Revised (ALSFRS-R)], has relevant 
intrinsic limitations: it is multidimensional, representing the sum of mean scores of three different domains, thus not 
satisfying rigorous measurement standards [3, 4].  
To address this urgent unmet need, recently, two staging systems have been developed [5, 6], based on simple clinical 
milestones marking the course of the disease. 
The first [5] staging system, hereafter called “King’s College staging system”,  considers the number of involved 
regions  for the first three stages and need for gastrostomy and for non-invasive ventilation for the subsequent stage (4A 
and 4B, respectively).   
The second staging system (namely MITOS system)[6] is based on the loss of independent functions in four key 
domains of the ALSFRS-R: the sum of the lost functions determines the stage. Both systems have only been tested 
separately in clinical trials/referral-centre populations. To our knowledge, studies on the validity and applicability of 
comparable models and systems for functional status in the general ALS population are lacking.  
MATERIALS AND METHODS   
Patients 
Since 2009, a prospective registry (ERRALS)[8] records all incident cases of ALS in the Emilia Romagna region, Italy. 
For each patient, detailed clinical information, including the ALSFRS-R score [7] is collected at each follow-up.    
Protocol approval 
All patients signed an informed consent permitting the treating neurologist to record their data in the registry, which 
was approved by the ethics committees of the coordinating centre and of the nine Provinces of Emilia Romagna. 
Staging systems 
King’s College staging system [5] considers the number of involved regions  for the first three stages (but 
distinguishing time of diagnosis –stage 2A- from involvement of the second region –stage 2B-) and need for 
gastrostomy and for non-invasive ventilation for stages 4A and 4B, respectively. Stage 5 corresponds to death. The 
stages were well distributed during the disease course, without reversion to earlier stages , with good correlation with 
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ALSFRS-R scores [8]. After having been tested on a prevalent, centre-based cohort, this system has been applied to 725 
patients enrolled in two clinical trials (LICALS and MITO) [9, 10], calculating stages by starting from ALSFRS-R 
scores obtaining an estimated stage which correlated about 92% with actual clinical stage [11]. Considering that 
diagnosis may be reached virtually at any point of the disease course, the authors merged stages 2A and 2B into stage 2, 
that was simply reached with involvement of a second region. In the present study, King’s College stages were 
calculated considering the loss of at least 1 point in any item of the ALSFRS-R referring to a certain body region.   
The MITOS system is based  on the loss of independent functions in four key domains of the ALSFRS-R; the sum of 
the lost functions determined the stage of ALS-MITOS, including 6 stages from 0 (absence of functional loss in any 
domain) to 4 (loss of function in 4 domains); Stage 5 is represented by death. The authors tested MITOS system using 
data obtained from two clinical trials (LITALS and QOC study) [12, 13]; then in a cohort of 200 ALS patients 
randomized in the EPOS study [14].  MITOS stages were calculated considering when loss of function, as defined by 
Chiò and colleagues [6], occurred at ALSFRS-R.   
Statistical methods  
Chi-square test, was used to explore differences between groups for categorical data, equality of medians and Kruskal-
Wallis tests for continuous data.   
Median time to each clinical stage was standardized by dividing the time from onset to each clinical milestone by the 
disease duration and multiplying by 100, using only information from patients who had died.  
Equality of medians test was used to explore differences between median times from onset to each stage, for each of the 
staging systems.  
Clinical stage was treated as time-dependent variable, i.e., for each patient we calculated the person-time at risk during 
each stage. Kaplan-Meier survival curves followed by log-rank test were used to evaluate survival during each clinical 
stage of both staging systems. 
For comparison of staging systems we used the Cox regression model to calculate the log likelihood in order to 
determine homogeneity and the Cochran-Armitage test for trend to measure the discriminatory ability of each staging 
system. 
Data were analyzed using Stata 11 (StataCorp, Texas, USA). 
RESULTS 
Patient characteristics 
We analyzed 545 consecutive newly diagnosed ALS from 1
st
 January 2009 to 31
st
 December 2013 in Emilia Romagna 
Region of Italy. Patient characteristics are shown in Table 1.   
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Standardized median time to each milestone: comparison of staging systems 
Figure 1 shows standardized median times (SMT) to stages 1, 2, 3, 4a, 4b and 5 (death), where 0 is onset of disease and 
100 is death, according to King’s College classification.  
Figure 2 shows SMT to stages 0, 1, 2, 3, 4 and 5 (death) according to the MITOS staging system. 
In both cases, we only used information from patients who had reached the end of the disease course, having died.  
Table 2 shows median and SMT from onset to each milestone and comparison of medians between pairs of consecutive 
stages. 
Number/proportion of deaths throughout stages 
In King’s College staging system there is a steady increase in the number and in the proportion of patients who die 
throughout stages 1 to 4a/b, when considering the last recorded milestone (stage 1: 14/65-22%; stage 2: 24/67-36%; 
stage 3: 53/118-45%; stage 4a: 33/55-60%; stage 4b: 148/239-62%). Ninety percent of tracheostomized patients 
undergo tracheostomy during stage 4 of King’s College stages (4a: 28% and 4b: 62%). 
In the MITOS system the number and/or proportions of deaths are fairly homogeneous throughout stages 2-4 (stage 0: 
58/174-33%; stage 1: 69/149-46%; stage 2: 63/92-69%; stage 3: 39/62-63%; stage 4:43/67-64%). The percentage of 
patients undergoing tracheostomy was evenly spread out throughout stages 0-3 (0: 21.5%, 1: 21.5%, 2: 23%, 3:25%, 4: 
9%). 
Survival curves: comparison of staging systems   
Figures 3a and 3b depict Kaplan Meier curves for time to death/last observation during each clinical stage for the 
King’s College (Fig. 3a) and for the MITOS (Fig. 3b) staging system, followed by log-rank test and Cox analyses 
between pairs of subsequent stages. 
Comparison of prognostic stratification of staging systems 
Table 3 shows the two staging systems’ discriminatory ability and homogeneity for prediction of time to death/last 
observation. King’s College system shows both a higher homogeneity within stages and a higher linear trend.  
DISCUSSION 
The present study was aimed at assessing advantages and drawbacks of two recently proposed staging systems for ALS 
patients when applied in an incident, population-based, cohort. 
Standardized median time to each milestone and cohort effects on timings 
According to King’s College staging system, standardized  median time from onset to weakness in a second region, 
weakness in a third region and the need for gastrostomy or respiratory support (stages 2, 3, 4a or 4b, respectively) occur 
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at distinct times, corresponding approximately to 40, 60 and 80% of the disease course, respectively. Our data is very 
similar to theirs, with above-said milestones occurring at 42, 58, 81 and 73% of the disease course.  
Stages 0-4 of the MITOS staging system are reached after a SMT of 35, 67, 79, 100 and 104% of the disease course in 
our cohort.  
Overall, King’s College milestones are more evenly spaced out throughout the disease course while the MITOS 
milestones are skewed towards later stages of the disease, with SMT to stages 3 and 4 being equal to or longer than 
median time to death.  This is probably due to the fact that each stage is reached only once a complete loss of function 
has occurred and this occurs towards the end of the disease course. 
Median time spent in each stage varies from 2-8 months for King’s College, similarly to data from two large phase 3 
clinical trials assessed by Balendra et al [8], in which median duration of transition time from one stage to another 
varied from 3 to 7 months. For MITOS systems the median duration of stages 0-2 ranged from 3 to 9 months while the 
median time from onset to stages 3, 4 and 5 overlapped. 
As for subgroups of patients, median time to weakness in a third region is anticipated in patients with a bulbar onset 
both in our cohort (SMT: 43) and in King’s College cohort (SMT: 45). This is consistent with the worse prognosis of 
the bulbar forms.  
Survival curves during each stage  
In King’s College system there is a decrease in survival from the earliest to the most advanced stages when considering 
time to death/last observation during each stage and survival curves are all significantly distinct from one another.  
In the MITOS staging system survival during stage 2 does not differ significantly from survival during stage 3 and, 
paradoxically, there seems to be an inversion of the curves with patients dying sooner during stage 2 of the disease as 
opposed to those that have reached stage 3 (Figure 3b). Although not specifically addressed, data in the study by Chiò et 
al [6] is in line with our observations: the probability of transition from stage 2 to death and from stage 3 to death at one 
year is 33% for both stages in the Quality of Care in ALS study [13], while in the LiTALS study [9], the probability 
even decreases from 29 to 25% for stage 2 and 3, respectively. We hypothesize that this may be due to the fact that 
patients who do not die after the complete loss of function in two domains, may belong to a group of “long survivors”. 
Tracheostomized patients 
Eighty-two (15%) patients underwent tracheostomy; of these, 47 (57%) had died by the end of the follow-up.  In our 
incident cohort, 90% of patients underwent tracheostomy during the last King’s College stage while according to the 
MITOS system, the percentage of tracheostomies were similar throughout stages 0-3. 
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Since without tracheostomy these patients would have died, it is not clear whether they should have been considered as 
patients who have reached the end of the disease course or not, based on the two considered staging systems. Neither of 
them addresses specifically this question, apparently considering tracheostomy as a region involvement (King’s college 
Staging system) or a loss of function (MITOS system) whereas tracheostomy influences the global disease course as it 
remove the most frequent cause of death in patients suffering from ALS.  
The issue of dementia   
Neither King’s College nor MITOS staging system included patients with dementia. In our cohort, the inclusion of 
patients with dementia anticipates median time to weakness in a third region using King’s College staging system 
(milestones reached at 46, 54, 88 and 79% of the disease course) whereas the presence of dementia did not influence 
MITOS staging system (milestones reached at 67,81,102, and 110% of the disease course). Since 15% patients with 
ALS have concomitant fronto-temporal dementia [15], a staging system used in clinical practice should take cognitive 
involvement into account, and this issue may be the object of further studies. 
Strengths and Limits 
Strength of the present study is its population-based, real-life setting with inclusion of patients with dementia and a long 
follow-up.  
A limit of the study is that data on time to clinical milestones is incomplete in some patients, especially in the more 
advanced stages. Furthermore, time to clinical stage was not collected prospectively, but was estimated retrospectively 
from ALSFRS-R. 
Conclusions 
In the present population, King’s College milestones appear to be more evenly spaced out throughout the disease course 
and to be comparable to those described by Roche et al [5], while the MITOS milestones are skewed towards later 
stages of the disease. 
Survival decreases steadily with escalating stages and survival curves are all distinct from one another in King’s 
College staging system while in the MITOS system, survival curves during stages 2 and 3 do not significantly differ 
from one another.   
Escalating stages are accompanied by an increasing number and proportion of deaths in King’s College system while 
they are homogeneously spread out throughout stages 2-4 of the MITOS system. 
King’s College staging system has a higher homogeneity, i.e. small differences in survival among patients in the same 
stage within each system and a higher discriminatory ability, i.e. greater differences in survival among patients in 
different stages within each system compared to the MITOS system,  suggesting a higher prognostic competency for the 
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King’s College staging system, especially for individual prognosis and for clinical trials use as an outcome measure. 
However, the MITOS system,  based on the complete loss of function in different domains, may be more useful for 
estimating health costs and resource allocations. [6].  
Neither system specifically addresses patients with dementia and the step of tracheostomy and its importance during the 
disease course; further studies should deal with these issues. 
 
Figures titles and legends 
Figure 1 
Title: Standardized median times to each milestone according to King’s College staging system 
Legend: Figure 1 showing SMT to involvement of one (stage 1), two (stage 2) and three (stage 3) CNS regions 
(upper/lower limbs, diaphragmatic or bulbar), and to need for gastrostomy (stage 4a) or respiratory support (stage 4b). 
Figure 2 
Title: Standardized median times to each milestone according to the MITOS staging system 
Legend: Figure 2 showing SMT to functional involvement in one domain (stage 0) and complete loss of function in one 
(stage 1), two (stage 2), three (stage 3) and four (stage 4) different domains (walking/self-care, swallowing, 
communicating, breathing).  
Figure 3a 
Title: Time to death/last observation during each stage: King’s College staging system 
Legend: Log-rank test and Cox analysis 
Stage 1 vs 2: p=0.0018 (HR: 2.7 [CI95: 1.4-5.3]) 
Stage 2 vs 3: p=0.0026 (HR: 2 [CI95: 1.3-3.4]) 
Stage 3 vs 4a: p=0.0058 (HR: 1.8[CI95: 1.2-2.8]) 
Stage 4a vs 4b: p<0.0001 (HR: 2.8[CI95: 1.9-4.2]) 
Figure 3b 
Title: Time to death/last observation during each stage: MITOS staging system 
Legend: Log-rank test and Cox analysis 
Stage 0 vs 1: p<0.0001 (HR: 3 [CI95: 2.1-4,4]) 
Stage 1 vs 2: p<0.0001 (HR: 2.4 [CI95: 1.7.-3.3]) 
Stage 2 vs 3: p=0.2 
Stage 3 vs 4: p=0.0008 (HR: 2.2[CI95: 1.4-3,5]) 
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